1 research outputs found
Angiopep-2, an MRI Biomarker, Dynamically Monitors Amyloid Deposition in Early Alzheimer’s Disease
The reliable and dynamic detection of amyloid β-protein
(Aβ)
deposition using imaging technology is necessary for preclinical Alzheimer’s
disease (AD), which may significantly improve prognosis. The present
study aimed to evaluate the feasibility of applying angiopep-2 (ANG),
a chemical exchange saturation transfer-magnetic resonance imaging
(CEST-MRI) biomarker, for monitoring Aβ deposition in vivo.
ANG exerted a good chemical exchange saturation transfer (CEST) effect
and displayed a moderate binding affinity to Aβ1–42 in
vitro. Six-month-old mice with AD injected with ANG exhibited a significantly
enhanced CEST effect than controls in vivo; this effect gradually
became more apparent at 8, 10, and 12 months. Spatial learning impairment
caused by abundant Aβ deposition (representing mild cognitive
impairment in AD patients) develops at 12 months in APPswe/PSEN1dE9
(line 85) AD mice. To conclude, the CEST of ANG could display very
earlier age-related Aβ pathological progress in mice with AD,
consistent with immunohistochemistry. ANG has extraordinary potential
for clinical transformation as an imaging biomarker to diagnose early
AD and track its progress dynamically and nonradiationally